Medical Condition

acute cannabis induced cns depression

Total Trials

1

Recruiting Now

1

Trial Phases

Various

Depression trials address major depressive disorder (MDD), treatment-resistant depression (TRD), and postpartum depression with a growing toolkit that extends beyond conventional SSRIs/SNRIs. The rapid approval of ketamine/esketamine for TRD has sparked interest in NMDA receptor modulators, while psychedelic-assisted therapy (psilocybin, MDMA) trials represent a paradigm shift in psychiatric research.

Active trials investigate rapid-acting antidepressants (ketamine analogs), neuroactive steroids, transcranial magnetic stimulation (TMS) protocols, psychedelic-assisted psychotherapy, digital therapeutics, and precision psychiatry approaches using biomarkers or genetic testing to predict treatment response.

Depression trials typically require a minimum MADRS or HAMD score at baseline; TRD trials usually require failure of at least 2 prior adequate antidepressant courses.

Top Sponsors

Anebulo Pharmaceuticals 1 trial

Recruiting Clinical Trials

NCT06017622

Recruiting

Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression

Anebulo Pharmaceuticals

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology